| Document |
Document Title |
|
WO/2022/002193A1 |
The present invention relates to the technical field of chemical pesticides, and provides a preparation method for and an application of pyrazole acylhydrazone containing a trifluoromethyl thiadiazole unit. The pyrazole acylhydrazone con...
|
|
WO/2022/001998A1 |
Disclosed by the present disclosure is a diarylamine derivative used as a fungicide, the structural general formula of the diarylamine derivative being shown as follows. The compound disclosed has good bactericidal activity, is very effe...
|
|
WO/2021/261562A1 |
There is still a great amount of damage by pests and in production of agricultural crops, horticultural crops, and the like. The development of a novel agricultural/horticultural insecticide is desired due to factors such as the emergenc...
|
|
WO/2021/263079A1 |
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds for inhibiting three prime repair exonuclease 1 ("TREX1").
|
|
WO/2021/261851A1 |
The present invention provides an organic electric element and an electronic device comprising the organic electric element, the organic electric element comprising an anode, a cathode, and an organic layer and a capping layer formed bet...
|
|
WO/2021/259163A1 |
Provided is a 2-N-substituted fused pyrazole-type compound, specifically a one-pot synthesis method for the preparation of a 2-N-substituted indazole-type compound. After azidizing a halogen in a substrate, no post-processing is necessar...
|
|
WO/2021/261857A1 |
The present specification relates to a heterocyclic compound and an organic light-emitting device comprising same.
|
|
WO/2021/259815A1 |
The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufac...
|
|
WO/2021/261563A1 |
In the production of crops in agriculture, horticulture and the like, the occurrence of damages by pests and the like has been still a major issue, and therefore the development of novel agricultural/horticultural insecticides has been d...
|
|
WO/2021/223650A9 |
The present application relates to a nitrogen-containing compound. The structural formula of the nitrogen-containing compound is as shown in formula I, in which ring A and ring B are each independently selected from a benzene ring or a f...
|
|
WO/2021/257977A1 |
Arylsulfonamides of carboxamido-piperidines, -pyrrolidines, and -azetidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment o...
|
|
WO/2021/257490A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression...
|
|
WO/2021/254118A1 |
Applications of an HPK1 kinase inhibitor in preventing and/or treating an animal pathogen infection. The HPK1 kinase inhibitor is a small molecule HPK1 kinase inhibitor, specifically, the compound of formula I or a pharmaceutically accep...
|
|
WO/2021/255279A1 |
The invention relates to novel compounds of formulae (I') and (II') for the treatment, alleviation or prevention of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a compone...
|
|
WO/2021/256902A1 |
The present invention relates to: a carbonohydrazonoyl dicyanide compound including at least two types of aryl or heteroaryl linked by a novel linker; and a use thereof.
|
|
WO/2021/253095A1 |
This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit...
|
|
WO/2021/254493A1 |
Provided are a compound that has a novel structure and acts as a PRMT5 inhibitor, a method for preparing a compound therefor, and a use thereof in treating a disease mediated by an PRMT5 inhibitor. Through experiments, such compounds sho...
|
|
WO/2021/252491A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2021/252644A1 |
The disclosure provides compounds of formula II with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provid...
|
|
WO/2021/250466A1 |
The present disclosure includes certain substituted (phthalazin-1-ylmethyl)ureas, N- (phthalazin-1-ylmethyl)amides, and analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV)...
|
|
WO/2021/249517A1 |
Provided is a new kind of molecular glues for triggering polyubiquitination and degradation of CCNK (cyclin K). Specifically, a new kind of molecular glues for creating a modified CDK12 protein so as to bind DDB1 of DDB1-CUL4-RBX1. The m...
|
|
WO/2021/249234A1 |
A compound represented by general formula (I) or stereisomers thereof and pharmaceutically acceptable salts, solvates or prodrugs thereof, a preparation method therefor and a pharmaceutical composition containing the compound. An applica...
|
|
WO/2021/252849A1 |
The disclosure provides compounds of Formula (I), deuterated derivatives of those compounds, and pharmaceutically acceptable salts of those compounds and derivatives, compositions comprising the same, and methods of using the same, inclu...
|
|
WO/2021/252678A1 |
Disclosed herein are certain heteroaryl alkylene substituted 2-oxoquinazoline derivatives of Formula (I): (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such c...
|
|
WO/2021/252555A1 |
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound heali...
|
|
WO/2021/251661A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2021/252494A1 |
Provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering a compound of Formula (I), or a salt thereof, or a composit...
|
|
WO/2021/248231A1 |
The present disclosure relates to compounds of Formula (I): (I), wherein R1, R2, L1, L2, Y1, Y2, Y3, X1, Ring A, Ring B and Ring C are as defined herein, as well as to compositions comprising such compounds. The compounds and composition...
|
|
WO/2021/252818A1 |
The present invention provides a compound of Formula (I): (I); an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particu...
|
|
WO/2021/247921A1 |
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurolo...
|
|
WO/2021/244505A1 |
The present invention relates to a compound as represented by general formula (1), and a preparation method therefor, and the use of the compound as represented by general formula (1) and an isomer, a crystal form, a pharmaceutically acc...
|
|
WO/2021/247845A1 |
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided ...
|
|
WO/2021/245070A1 |
The present invention relates to isoxazolidines of formula I and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase (1) such as rheumatoid arthriti...
|
|
WO/2021/244199A1 |
The present invention relates to a compound as shown in general formula (I) below (in formula (I), each of R1 and R2 independently represents a hydrogen atom or a C1-10 linear or branched alkyl optionally having a substituent, or the two...
|
|
WO/2021/247732A1 |
The present invention relates to compounds of formula I (I) as well as to the compounds of formula I for use as transmembrane serine protease 2 (TMPRSS2) inhibitors in the treatment of viral infections, such as e.g. corona virus infectio...
|
|
WO/2021/244645A1 |
A novel five-membered heteroaromatic imidazole compound and use thereof in preparing a medicament for treating related diseases. Specifically, disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt ther...
|
|
WO/2021/244952A1 |
82138 FF 53 ABSTRACT MICROBIOCIDAL DERIVATIVES Compounds of the formula (I)5 R 8 R 1 R 7 R 6 R 5 R 4 R 3 R 2 N O N A F N S O (I) wherein the substituents are as defined in claim 1, useful as pesticides, and especially fungicides.
|
|
WO/2021/245055A1 |
The present invention encompasses compounds of formula (I), wherein R1a, R1b, R2a, R2b, Z, R3, R5, A, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharma...
|
|
WO/2021/245051A1 |
The present invention encompasses compounds of formula (I), wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, p...
|
|
WO/2021/248133A1 |
The present disclosure relates extracellular vesicles, e.g., exosomes, comprising an antigen-binding moeity, e.g., a single-domain antigen-binding moeity, e.g., a vNAR, a VHH, or a fragment thereof, that specifically binds transferrin re...
|
|
WO/2021/238834A1 |
The present invention relates to an arylformamide compound and a preparation method and a medical use thereof. Particularly, the present invention relates to a compound shown in a general formula (I), a preparation method thereof, a phar...
|
|
WO/2021/242982A1 |
The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
|
|
WO/2021/243001A1 |
Provided are compounds of Formula (I): (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with TREX1.
|
|
WO/2021/239695A1 |
The present invention relates to a compound of formula (I). It also relates to a pharmaceutical composition comprising at least one compound of formula (I) and at least one pharmaceutically acceptable support. Finally, it relates to the ...
|
|
WO/2021/239133A1 |
Disclosed in the present invention is a pyrimidine compound as an AXL inhibitor. The structure of the pyrimidine compound is as shown in general formula I, and the definition of each substituent is as described in the description. The pr...
|
|
WO/2021/239745A1 |
The present invention relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical ...
|
|
WO/2021/243230A1 |
In some embodiments, the present disclosure provides a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the compound of Formula (I), and methods of treati...
|
|
WO/2021/241741A1 |
The present invention provides a photoelectric conversion element having excellent sensitivity, an image sensor, an optical sensor, and a compound. The photoelectric conversion element of the present invention has a conductive film, a ph...
|
|
WO/2021/233851A1 |
The invention relates to a compound of formula (I) wherein R1-R2 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2021/233397A1 |
Provided are piperazine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), pharmaceutically acceptable salts, hydrates and stereoisomers thereof. Provided are also pharmaceutic...
|
